Recent Finacing
Recent Raise
Hubble Therapeutics develops HUB-101, a WARF-licensed AAV gene therapy targeting KCNJ13-driven retinal dystrophies (LCA16, Snowflake), holding FDA rare/orphan designations and partnering for IND-enabling studies and manufacturing.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
